There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific ...

Petr Holy, consultant ujsonologist and specialist in prostate cancer diagnosis from Men's Health Clinic in Kingston, has ...

It is the fourth most common cancer seen in men, and it makes up about 4% of all cancer ... where she most recently served as ...

The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...

Dr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of ...

Oct. 9, 2024 — How bladder cancer originates and progresses has been illuminated as never before. Researchers found that antiviral enzymes that mutate the DNA of normal and cancer cells are key ...

facilitating non-surgical tumour treatment. Bladder cancer is the second most common urologic cancer in men in the US, primarily affecting the older population. UroGen president and CEO Liz ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

So women who have overactive bladder don't necessarily have to leak urine, but for the most part, women, unfortunately, are at higher risk of leaking than are men, our male colleagues ... that to rule ...